Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 24,000 shares, effective February 2, 2026.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 24,000 shares, effective February 2, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.65.
The awards were approved by the Compensation Committee and issued under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
Details
News Market Reaction – OLMA
In the Feb 4 session, OLMA gained 0.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Inducement options
- 24,000 shares
- Aggregate stock options granted to two new employees
- Exercise price
- $25.65 per share
- Option strike, equal to last reported sale price on Feb 2, 2026
- Vesting period
- 4 years
- Inducement stock options vesting schedule
- Cliff vesting
- 25%
- Initial vest on first anniversary of vesting commencement date
- Remaining installments
- 36 monthly installments
- Post-cliff vesting over following three years
- Option term
- 10 years
- Maximum life of the inducement stock options
- Severance payment
- $621,283
- Total lump-sum to departing COO/CFO per 8-K on Jan 30, 2026
- Market capitalization
- $2,056,102,025
- Market cap prior to this inducement grant announcement
Historical Context
-
Inducement options for 8 new employees under 2022 Inducement Plan.
-
Announcement of presentation at J.P. Morgan Healthcare Conference.
-
Inducement options for two employees totaling 65,000 shares.
-
Participation in Evercore Healthcare Conference fireside chat.
-
Closing of $218.5M common stock offering at $19.00 per share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 24,000 shares of the Company's common stock, effective as of February 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.